Patheon ops 'transformation' aligns with Q4 losses

Contract manufacturer Patheon is "successfully executing on [its] transformation," says CEO Jim Mullen. "In the locations where we have rolled out our operational excellence programs, we have already realized enhanced capacity, decreased cycle times and improved efficiency," he says in a recent financial filing that reported a fourth-quarter loss of $5.4 million--three times that of the same quarter last year. "Key internal performance metrics are improving." Release | Story

Suggested Articles

Eli Lilly is investing $400 million in its Indianapolis site to expand production of insulin and other diabetes meds, and add 100 jobs.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.